Target Price | €87.10 |
Price | €79.45 |
Potential |
9.63%
register free of charge
|
Number of Estimates | 6 |
6 Analysts have issued a price target Pharma Mar 2026 .
The average Pharma Mar target price is €87.10.
This is
9.63%
register free of charge
€118.00
48.52%
register free of charge
€29.60
62.74%
register free of charge
|
|
A rating was issued by 6 analysts: 3 Analysts recommend Pharma Mar to buy, 2 to hold and 1 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Pharma Mar stock has an average upside potential 2026 of
9.63%
register free of charge
|
Dec '24 |
2025 Estimates |
|
---|---|---|
Revenue Million € | 174.86 | 198.96 |
10.57% | 13.78% | |
EBITDA Margin | 5.34% | 26.14% |
1,960.35% | 389.38% | |
Net Margin | 14.98% | 33.55% |
2,146.02% | 123.96% |
6 Analysts have issued a sales forecast Pharma Mar 2025 . The average Pharma Mar sales estimate is
This results in the following potential growth metrics:
4 Analysts have issued an Pharma Mar EBITDA forecast 2025. The average Pharma Mar EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
3 Pharma Mar Analysts have issued a net profit forecast 2025. The average Pharma Mar net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '24 |
2025 Estimates |
|
---|---|---|
Earnings Per Share € | 1.49 | 3.80 |
2,383.33% | 155.03% | |
P/E | 20.93 | |
EV/Sales | 6.50 |
3 Analysts have issued a Pharma Mar forecast for earnings per share. The average Pharma Mar EPS is
This results in the following potential growth metrics and future valuations:
Analyst | Rating | Action | Date |
---|---|---|---|
RX SECURITIES |
Locked
➜
Locked
|
Locked | Jan 05 2025 |
CHARDAN CAPITAL MARKETS |
Locked
➜
Locked
|
Locked | Oct 30 2024 |
ALANTRA EQUITIES |
Locked
➜
Locked
|
Locked | Oct 29 2024 |
NEEDHAM & COMPANY INC. |
Locked
➜
Locked
|
Locked | Oct 29 2024 |
CAIXABANK BPI |
Locked
➜
Locked
|
Locked | Sep 22 2024 |
Analyst Rating | Date |
---|---|
Locked
RX SECURITIES:
Locked
➜
Locked
|
Jan 05 2025 |
Locked
CHARDAN CAPITAL MARKETS:
Locked
➜
Locked
|
Oct 30 2024 |
Locked
ALANTRA EQUITIES:
Locked
➜
Locked
|
Oct 29 2024 |
Locked
NEEDHAM & COMPANY INC.:
Locked
➜
Locked
|
Oct 29 2024 |
Locked
CAIXABANK BPI:
Locked
➜
Locked
|
Sep 22 2024 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.